CBMT 2022 NTERNATIONAL CONGRESS OF BMT 2022 27* ANNUAL CONGRESS OF KSBMT

SEPTEMBER 1(THU) - 3(SAT), 2022 BEXCO, BUSAN http://icbmt.or.kr

Name	Paul J. Martin, MD	
Current Position	Professor Emeritus	
Country	USA	
Major Field	Hematopoietic Cell Transplantation	

Educational Background

Batchelor of Science, Marquette University, Milwaukee WI, 1970 Doctor of Medicine, University of Pennsylvania, Philadelphia PA, 1974

Professional Experience

Dr. Martin has more than 40 years of clinical and research experience in hematopoietic cell transplantation, with an emphasis on research related to acute and chronic graft-versus-host disease (GVHD). He has served as principal investigator for several clinical trials testing different approaches for preventing or treating acute or chronic GVHD after allogeneic hematopoietic cell transplantation. He has also led many retrospective studies of acute and chronic GVHD with the use of data from experience at the Fred Hutchinson Cancer Research Center. Dr. Martin had leadership roles in all three National Institutes of Health consensus development projects on criteria for clinical trials in chronic graft-versus-host disease.

Other Experience and Professional Memberships

American Society of Hematology American Society of Blood and Marrow Transplantation

Main Scientific Publications

Martin PJ, Storer BE, Rowley SD, Flowers MED, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, Devetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D. (2009). Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. Blood, 113: 5074-5082. PMC2686178

Martin PJ, Lee SJ, Przepiorka D, Horowitz MM, Koreth J, Vogelsang GB, Walker I, Carpenter PA, Griffith LM, Akpek G, Mohty M, Wolff D, Pavletic SZ, Cutler CS. (2015). National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: VI. The 2014 Clinical Trial Design Working Group Report. Biol Blood Marrow Transplant 21(8):1343-59. PMC4506719

Martin PJ, Levine DM, Storer BE, Zheng X, Jain D, Heavner B, Norris BM, Geraghty DE, Spellman SR, Sather C, Wu F, Hansen John A. A Model of Minor Histocompatibility Antigens in Allogeneic Hematopoietic Cell Transplantation. <u>Front Immunol.</u> 2021;12:4836. doi: 10.3389/fimmu.2021.782152. PMID: 34868058

Song Q, Wang X, Wu X, Kang TH, Qin H, Zhao D, Jenq R, van den Brink M, Riggs A, Martin PJ, Chen Y, and Zeng D. (2021). IL-22-dependent dysbiosis and mononuclear phagocyte depletion

1-A

contribute to steroid- resistant gut graft-versus-host disease in mice. Nature Comms. 12:805. PMCID: PMC7865028

Martin PJ. How I treat steroid-refractory acute graft-versus-host disease. <u>Blood</u>. 2020. PMID: 32202630

Vo P, Gooley TA, Carpenter PA, Sorror ML, MacMillan ML, DeFor TE, Martin PJ. (2022). Prediction of outcomes after second-line treatment for acute graft-versus-host disease. Blood Advances. In press.

ICBMT 2022 Secretariat [People-X, Inc.] 1F, Haeoreum B/D 16, Yeoksam-ro 17 gil, Gangnam-gu, Seoul, 06246, Korea T. +82-2-566-6031 F. +82-2-566-6087 E. icbmt@icbmt.or.kr

The Korean Society of Blood and Marrow Transplantation KSBMT